Atlas Trials

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Clinical trial NCT03879577 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03879577
Sponsor
University of Chicago
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Breast CancerBreast Cancer FemaleHER2-positive Breast CancerBreast Cancer Stage IIBreast Cancer Stage III
Start date
2019-11-25
Primary completion
2023-03-30
Enrollment
53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.